N/A
Manufactured by Acacia Pharma Ltd
16,736 FDA adverse event reports analyzed
Last updated: 2026-04-15
AMISULPRIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Acacia Pharma Ltd. The most commonly reported adverse reactions for AMISULPRIDE include DRUG INEFFECTIVE, DRUG INTERACTION, WEIGHT INCREASED, TOXICITY TO VARIOUS AGENTS, NEUTROPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AMISULPRIDE.
Out of 5,762 classified reports for AMISULPRIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 16,736 FDA FAERS reports that mention AMISULPRIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, DRUG INTERACTION, WEIGHT INCREASED, TOXICITY TO VARIOUS AGENTS, NEUTROPENIA, SCHIZOPHRENIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Acacia Pharma Ltd in connection with AMISULPRIDE. Always verify the specific product and NDC with your pharmacist.